Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Ron J. Feldman"'
Autor:
Andrew R. Tadros, MD, PhD, George Atteh, MD, Diana L. Vargas, MD, Emily F. Cole, MD, MPH, Ron J. Feldman, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 37, Iss , Pp 92-97 (2023)
Externí odkaz:
https://doaj.org/article/0f111088d3f14ef6bb98252b7b11a6e2
Autor:
Danielle E. Mustin, MEng, Emily F. Cole, MD, MPH, Travis W. Blalock, MD, Merin E. Kalangara, MD, Benjamin K. Stoff, MD, MA, Ron J. Feldman, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 19, Iss , Pp 41-43 (2022)
Externí odkaz:
https://doaj.org/article/9a8065a627a6437c8b36bd1f839be16b
Autor:
George Atteh, BS, Emily F. Cole, MD, MPH, Adam J. Perricone, MD, PhD, Ron J. Feldman, MD, PhD
Publikováno v:
JAAD Case Reports, Vol 10, Iss , Pp 34-37 (2021)
Externí odkaz:
https://doaj.org/article/8ee44eccc90f46d5af5f324c47a46aed
Publikováno v:
JID Innovations, Vol 1, Iss 4, Pp 100050- (2021)
Bullous pemphigoid (BP) is an autoimmune blistering disease resulting in pruritus and cutaneous blistering. Longitudinal studies characterizing the disease course of patients with BP on conventional therapy are lacking. We sought to characterize the
Externí odkaz:
https://doaj.org/article/9088cbc48ac24d99a56643db2edceb36
Publikováno v:
Dermatology Online Journal. 29
Autor:
Benjamin K. Stoff, Emily F. Cole, Travis W. Blalock, Danielle E. Mustin, Merin E. Kalangara, Ron J. Feldman
Publikováno v:
JAAD Case Reports, Vol 19, Iss, Pp 41-43 (2022)
JAAD Case Reports
JAAD Case Reports
Publikováno v:
British Journal of Dermatology. 187:606-607
Publikováno v:
Journal of the American Academy of Dermatology. 83:251-254
Publikováno v:
JID Innovations, Vol 1, Iss 4, Pp 100050-(2021)
JID Innovations
JID Innovations
Bullous pemphigoid (BP) is an autoimmune blistering disease resulting in pruritus and cutaneous blistering. Longitudinal studies characterizing the disease course of patients with BP on conventional therapy are lacking. We sought to characterize the
Publikováno v:
Journal of the American Academy of Dermatology. 81:179-186
Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease requiring treatment with immunosuppressive medications; however, finding a therapy that has a sustained durable response and an acceptable side effect profile has bee